Initiating Treatment
Active Resources: 8
Antiretroviral Guidelines
-
10/27/2017
Online Training
-
10/20/2017
-
8/23/2017
-
9/15/2016
Slide Sets
-
4/28/2017
Toolkits
-
5/17/2016
Image Library
-
4/6/2016
Charts, Tables & Posters
-
1/28/2015
Archive Resources: 7
Patient Information
-
9/29/2013 (reviewed: 2/24/2017)
-
1/1/2005
Fact Sheets
-
6/1/2013
Charts, Tables & Posters
-
6/1/2013 (reviewed: 1/11/2017)
Antiretroviral Guidelines
-
3/5/2012
Self-Study Materials
-
3/1/2010
Slide Sets
-
1/1/2006
Articles: 3
-
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...
-
Bictegravir in Initial Therapy
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...
| Day | Title |
|---|---|
|
12/3 |
| Day | Title |
|---|---|
|
10/15 |